This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Craft, T.M. Articles by Griffiths, J.V. Search for Related Content PubMed Articles by Craft, T.M. Articles by Griffiths, J.V. Social Bookmarking                         What's this?

ECG Studies with Astemizole

Department of Anaesthesia and Intensive Care, Milton Keynes, Bucks, UK

G. Vanden Bussche

Janssen Pharmaceutica nv, Beerse, Belgium

J. De Cree

Clinical Research Unit, St. Bartholomeus, Jan Palfijn Hospital IB-2060 Merksem, Belgium

J.V. Griffiths

Janssen Pharmaceutical Limited, Grove, Wantage, Oxfordshire, UK

1 Six healthy volunteers took part in a 2-week haemodynamic safety study of astemizole.

2 They were given 30 mg daily (3 x 10 mg tablets) for the first 3 days and 10 mg daily for the next 12 consecutive days.

3 Heart rate, blood pressure, ECG and systolic time intervals at rest were measured before the start and five times during the day.

4 No changes were observed in any of the parameters measured. The configuration of the ECG was not influenced.

5 Serum concentrations of astemizole plus hydroxylated metabolites measured at the end of the study were 16 times lower than those detected in a patient overdosing on 200 mg astemizole.

Human & Experimental Toxicology, Vol. 6, No. 6, 527-528 (1987)
DOI: 10.1177/096032718700600614


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?